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Introduction {#sec005}
============

Central nervous system (CNS) dysfunction, such as uremic encephalopathy, cognitive impairment, and dementia, is a frequent complication of patients undergoing hemodialysis (HD). \[[@pone.0117474.ref001]\] Cerebrovascular accident (CVA) was described as the fourth leading cause of death in HD patients according to the annual report of the Japanese Society for Dialysis Therapy in 2011. \[[@pone.0117474.ref002]\] Magnetic resonance imaging (MRI) is a useful tool for detecting morphological changes in the brain and therefore evaluating CVA; in addition, silent cerebral infarction detected by MRI has been found to associate with the severity of cognitive impairment in HD patients. \[[@pone.0117474.ref003]\] However, imaging methods like MRI and computed tomography can only provide information about organic lesions in the brain, and cannot evaluate the functional status such as cerebral blood flow and cerebral oxygenation. Recently, near-infrared spectroscopy (NIRS) has been used as a tool to measure the regional saturation of oxygen (rSO~2~), a marker of tissue oxygenation, at the frontal cerebral cortex in a variety of clinical situations, and has shown the change of critical balance between arterial oxygen delivery and cerebral oxygen consumption. \[[@pone.0117474.ref004]--[@pone.0117474.ref007]\] Cerebral rSO~2~ was reported to be significantly lower in HD patients than in healthy controls. \[[@pone.0117474.ref001],[@pone.0117474.ref008]\] Few reports, however, have examined the relationship between cerebral oxygenation in HD patients and clinical parameters. Therefore, in this study, we aimed to elucidate the clinical factors influencing cerebral rSO~2~ in HD patients.

Methods {#sec006}
=======

In this study, we included HD patients who met the following criteria: (1) patients with end-stage renal disease receiving intermittent HD and (2) patients with unimpaired consciousness. The exclusion criteria were: (1) coexisting disease including chronic obstructive pulmonary disease, apparent neurological disorder, and chronic hypotension (defined as systolic blood pressure \<100 mmHg), and (2) history of cerebrovascular disease and dementia. Not all patients enrolled in this study underwent imaging examinations such as computed tomography and MRI for detecting cerebral ischemia, carotid artery stenosis or aortic stenosis. Therefore, we cannot completely exclude the existence of ischemic conditions in each patient. However, we excluded HD patients with apparent neurological disorder, history of cerebrovascular disease, and dementia; therefore, it could be considered that cerebral ischemia, carotid artery stenosis or aortic stenosis had no clinical effect in the HD patients enrolled in our study. Fifty four HD patients were recruited (38 men and 16 women; mean age, 67.7 ± 1.2 years, HD duration, 6.5 ± 1.9 years). The causes of chronic renal failure were diabetes mellitus (DM, 27 patients), chronic glomerulonephritis (14 patients), nephrosclerosis (4 patients), polycystic kidney disease (4 patients), and other (5 patients). Each patient received maintenance HD 2 or 3 times a week, and the duration of the HD sessions was 3 or 4 h. The patients' general characteristics are summarized in [Table 1](#pone.0117474.t001){ref-type="table"}. All participants signed informed consent to participate in this study. This study was approved by the Institutional Review Board of Saitama Medical Center, Jichi Medical University, Japan (No. RIN13-39), and Nishikawa Town Hospital, Japan (No. 1/4/2013), and conforms to the provisions of the Declaration of Helsinki (as revised in Tokyo in 2004). In addition, 28 healthy volunteers (18 men and 10 women, mean age, 43.4 ± 3.6 years) were recruited as the control group.
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###### Patients Characteristics and the correlation between cerebral rSO~2~ and clinical parameters.
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                                           mean ± SE     p value   r
  ---------------------------------------- ------------- --------- -------
  Total number pf patients (male/female)   54 (38/16)              
  Age (years)                              67.7 ± 1.2    NS        
  Disease                                                          
    diabetes mellitus                      27                      
    chronic glomerulonephritis             14                      
    nephrosclerosis                        4                       
    polycystic kidney disease              4                       
    others                                 5                       
  HD duration (years)                      6.6 ± 0.9     \<0.01    -0.35
  Weight gain (%)                          3.4 ± 0.2     NS        
  Systolic blood pressure (mmHg)           139.7 ± 2.8   NS        
  Diastolic blood pressure (mmHg)          73.2 ± 1.8    NS        
  pH                                       7.38 ± 0.0    \<0.01    -0.42
  pCO2 (mmHg)                              37.6 ± 0.6    NS        
  pO~2~ (mmHg)                             81.9 ± 2.2    NS        
  HCO3^-^ (mEq/L)                          21.6 ± 0.3    NS        
  Sat O2 (%)                               94.8 ± 0.6    NS        
  Hb (g/dL)                                9.9 ± 0.2     \<0.01    0.44
  Arterial O2 content (mL/dL)              12.8 ± 0.2    \<0.01    0.40
  ESAs dose (U/week)                       5375 ± 510    NS        
  BUN (mg/dL)                              52.1 ± 2.2    \<0.05    0.29
  Cr (mg/dL)                               8.5 ± 0.3     NS        
  Na (mEq/L)                               137.1 ± 0.5   \<0.01    0.45
  K (mEq/L)                                4.5 ± 0.1     \<0.05    0.28
  Ca (mg/dL)                               8.9 ± 0.1     \<0.05    -0.28
  P (mg/dL)                                4.7 ± 0.2     \<0.01    0.35
  Total protein (g/dL)                     6.2 ± 0.1     NS        
  Serum albumin (g/dL)                     3.3 ± 0.1     \<0.01    0.41
  Serum osmolarity (mosm/kg-H~2~O)         301.5 ± 1.4   \<0.05    -0.33
  Plasma glucose (mg/dL)                   156.6 ± 8.5   \<0.01    0.36
  HbA1c (%)                                5.9 ± 0.2     NS        
  C-reactive protein (mg/dL)               2.2 ± 0.6     \<0.01    -0.36

Monitoring of cerebral oxygenation and clinical laboratory measurement {#sec007}
----------------------------------------------------------------------

Cerebral rSO~2~ was monitored at the forehead with an INVOS 5100C saturation monitor (Covidien Japan, Tokyo, Japan), which utilizes NIRS technology. This instrument uses a light-emitting diode, which transmits near-infrared light at 2 wavelengths (735 and 810 nm), and 2 silicon photodiodes which act as light detectors; results are read as a single numerical value that represents the rSO~2~ \[[@pone.0117474.ref009],[@pone.0117474.ref010]\]. All data obtained by this instrument were immediately and automatically stored in sequence. Interobserver variance for this instrument, that is, reproducibility of the rSO~2~ measurement, is acceptable as previously reported. Therefore, rSO~2~ is considered reliable when estimating the actual cerebral oxygenation. \[[@pone.0117474.ref011]\]

Prior to HD, the recruited patients rested in the supine position for at least 10 min in order to reduce the influence of postural change. An rSO~2~ measurement sensor was attached to the patient's forehead for measurement in the resting state. Thereafter, rSO~2~ was measured for 5 min before HD, and we evaluated the mean rSO~2~ for 5 min, as a marker of cerebral oxygenation, in each patient. Blood samples were obtained from each patient under room air. It was previously reported that samples obtained from the radial artery or those from an arterial line at the arteriovenous fistula presented similar values when evaluating the parameters of oxygen status, including pH, oxygen pressure (pO~2~: mmHg), and oxygen saturation (SpO2: %). \[[@pone.0117474.ref012]\] Therefore, prior to HD we obtained all blood samples, including blood gas analysis, from the arterial site of arteriovenous fistulae in each patient.

Arterial O2 content (CaO~2~) and serum osmolality (sOsm) were calculated using the following equations: $$\text{CaO}_{2}\left( \text{mL/dL} \right) = 1.34\quad \times \quad\text{Hb}\quad \times \quad\text{SpO}2\mspace{9mu} \div \quad 100\quad + \quad\left( 0.0031\quad \times \quad\text{pO}_{2} \right)$$ \[[@pone.0117474.ref013]\] $$\text{sOsm}\left( \text{mosm/kg} - \text{H}_{2}\text{O} \right) = \left( {2\quad \times \quad\text{Na}} \right) + \mspace{9mu}\text{PG}\quad \div \quad 18\mspace{9mu} + \mspace{9mu}\text{BUN}\mspace{9mu} \div \mspace{9mu} 2.8$$ \[[@pone.0117474.ref014]\] where Hb represents the hemoglobin concentration (g/dL). Na represents the serum sodium concentration (mEq/L), PG represents the plasma glucose level (mg/dL), and BUN represents the blood urea nitrogen concentration (mg/dL).

Erythropoiesis-stimulating agents (ESAs) were administered for the treatment of renal anemia, and calculations of the optimum ESA dose (U/week) were based on a method reported previously, \[[@pone.0117474.ref015]\] where a ratio of 1:200 was used to convert the dose for long-acting ESAs, including darbepoetin-α and continuous erythropoietin receptor activator, into a short-acting recombinant human erythropoietin equivalent dose for each patient. \[[@pone.0117474.ref015]\] The rSO~2~ in healthy controls was measured for at least 5 min in the supine position in a manner similar to that in HD patients.

Analysis {#sec008}
========

Data were expressed as mean ± standard error (SE). The Student's t-test for non-paired values was used for comparing 2 groups, and Mann--Whitney U test was used for comparison of nonparametric variables between 2 groups. Correlations between 2 groups were evaluated by Pearson's correlation coefficient and linear regression analysis. Multiple regression analysis was performed using parameters that showed a significant correlation with cerebral rSO~2~. A difference of p \<0.05 was considered significant.

Results {#sec009}
=======

Cerebral rSO~2~ at rest in HD patients was compared with that in healthy controls, and there was a significant difference between the 2 groups (HD patients: 49.5 ± 1.7%, healthy controls: 68.9 ± 1.6%, p \< 0.001) ([Fig. 1](#pone.0117474.g001){ref-type="fig"}). Recently, cerebral rSO~2~ was reported to be significantly lower in HD patients than in healthy controls \[[@pone.0117474.ref001], [@pone.0117474.ref008]\], and our results are consistent with these reports.

![Comparison between cerebral rSO~2~ in hemodialysis patients and healthy controls.](pone.0117474.g001){#pone.0117474.g001}

[Table 1](#pone.0117474.t001){ref-type="table"} shows patients' characteristics, and correlations between the cerebral rSO~2~ and clinical parameters. Cerebral rSO~2~ showed significant positive correlations with CaO~2~, hemoglobin (Hb) level, serum sodium concentration, serum potassium concentration, serum inorganic phosphate concentration, serum albumin concentration, and plasma glucose level. A simple linear regression analysis revealed that cerebral rSO~2~ was negatively correlated with pH, serum calcium concentration, sOsm, HD duration, and C-reactive protein.

We performed a multivariate linear regression analysis using variables that showed a significant correlation with the cerebral rSO~2~ in a simple linear regression analysis ([Table 2](#pone.0117474.t002){ref-type="table"}). The multivariate regression analysis found that the cerebral rSO~2~ was independently associated with pH (standardized coefficient: -0.35), HD duration (standardized coefficient: -0.33), and serum albumin concentration (standardized coefficient: 0.28). On the other hand, the cerebral rSO~2~ was independent of Hb and CaO~2~. We also evaluated the influence of DM on the cerebral rSO~2~ values ([Table 3](#pone.0117474.t003){ref-type="table"}). The cerebral rSO~2~ was significantly lower in patients with DM than in those without DM (46.8 ± 1.7% vs. 52.1 ± 1.8, p \< 0.05) ([Fig. 2](#pone.0117474.g002){ref-type="fig"}). In addition to the difference in cerebral rSO~2~, there were significant differences in serum sodium concentration, plasma glucose level, and HbA1c levels between the 2 groups.

![Comparison of cerebral rSO~2~ in hemodialysis patients (HD) with and without diabetes mellitus (DM).\
\* \< 0.05 at HD patients with DM vs. those without DM.](pone.0117474.g002){#pone.0117474.g002}
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###### Multivariate linear regression analysis: Independent factors of cerebral rSO~2~ in hemodialysis patients.
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  Variables       Coefficient   Standardized coefficient   p
  --------------- ------------- -------------------------- -------
  pH              -62.5         -0.35                      0.012
  HD duration     -0.47         -0.33                      0.006
  Serum albumin   4.12          0.28                       0.041

10.1371/journal.pone.0117474.t003

###### Different clinical parameters for hemodialysis patients with and without diabetes mellitus.
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                                     with DM        without DM    p
  ---------------------------------- -------------- ------------- --------
  rSO~2~ (%)                         46.9 ± 1.7     52.1 ± 1.8    \<0.05
  Age (years)                        66.3 ± 1.4     69.1 ± 2.0    NS
  Male/Female                        18 / 9         20 / 7        NS
  HD duration (years)                7.7 ± 1.4      5.4 ± 1.1     NS
  Weight gain (%)                    3.6 ± 0.4      3.3 ± 0.3     NS
  Systolic blood pressure (mmHg)     144.8 ± 3.7    134.6 ± 4.1   NS
  Diastolic blood pressure (mmHg)    74.0 ± 2.6     72.4 ± 2.3    NS
  pH                                 7.37 ± 0.01    7.38 ± 0.01   NS
  pCO2 (mmHg)                        38.3 ± 0.6     36.9 ± 1.1    NS
  pO~2~ (mmHg)                       80.1 ± 3.2     83.7 ± 2.9    NS
  HCO3^-^ (mEq/L)                    21.8 ± 0.4     21.3 ± 0.5    NS
  Sat O2 (%)                         94.5 ± 0.6     95.1 ± 1.0    NS
  Hb (g/dL)                          10.2 ± 0.2     9.6 ± 0.2     NS
  Arterial O2 content (mL/dL)        13.1 ± 0.3     12.5 ± 0.3    NS
  ESAs dose (U/week)                 5287 ± 797     5463 ± 651    NS
  BUN (mg/dL)                        48.1 ± 3.0     56.0 ± 3.2    NS
  Na (mEq/L)                         136.1 ± 0.6    138.1 ± 0.7   NS
  K (mEq/L)                          4.4 ± 0.1      4.5 ± 0.2     NS
  Ca (mg/dL)                         8.9 ± 0.1      9.0 ± 0.1     NS
  P (mg/dL)                          4.7 ± 0.3      4.8 ± 0.2     NS
  Serum albumin (g/dL)               3.3 ± 0.1      3.2 ± 0.1     NS
  Serum osmolarity (mosm/kg-H~2~O)   299.6 ± 2.0    303.5 ± 2.0   NS
  Plasma glucose (mg/dL)             181.9 ± 14.5   131.5 ± 6.2   \<0.01
  HbA1c (%)                          6.6 ± 0.2      5.1 ± 0.1     \<0.01

Discussion {#sec010}
==========

Regional saturation of oxygen (rSO~2~) is widely used for monitoring cerebral function during cerebral surgery, as rSO~2~ measured using NIRS can provide accurate yet non-invasive information on cerebral oxygen saturation, and can be easily performed in the clinical setting. \[[@pone.0117474.ref001], [@pone.0117474.ref004]--[@pone.0117474.ref011]\] Recently, cerebral rSO~2~ was reported to be significantly lower in HD patients than in healthy controls. \[[@pone.0117474.ref001],[@pone.0117474.ref008]\] The reasons for this however, remain uncertain, and the factors affecting the deterioration of cerebral rSO~2~ in HD patients have not been determined. In this study, we identified modifiable factors, including pH, HD duration, and serum albumin concentration, as being independently associated with cerebral rSO~2~; we also demonstrated that cerebral rSO~2~ was significantly lower in HD patients with DM than in those without DM.

Among the modifiable factors identified as being independently associated with cerebral rSO~2~, pH was the factor most strongly affecting cerebral rSO~2~ in HD patients. A decrease of extracellular pH, even without partial pressure of carbon dioxide (pCO2) increase, was previously reported to induce a dilation of the cerebral artery, \[[@pone.0117474.ref016]\] and therefore, regional cerebral blood flow (rCBF) would increase in response to the decrease in pH. Thus, in the brain, it is possible that cerebral rSO~2~ increases via the increase of arterial oxygen delivery accompanying rCBF increase induced by pH decrease. This mechanism could explain why cerebral rSO~2~ shows an inverse relationship with pH change. Furthermore, changes in cerebral rSO~2~ were recently shown to be independently and negatively associated with changes in pH in patients undergoing liver transplantation, \[[@pone.0117474.ref017]\] and our results, which indicated an inverse relationship between cerebral rSO~2~ and pH, were consistent with this report. Thus far, however, the change of rSO~2~ affected by pH remains unclear, so further examination would be required regarding the association between cerebral rSO~2~ change and pH.

Serum albumin concentration also showed a significant positive correlation with cerebral rSO~2~. Serum albumin concentration was previously reported to be a prognostic marker of survival in HD patients, similar to nutritional status. \[[@pone.0117474.ref018],[@pone.0117474.ref019]\] The decrease in its concentration has often been observed in patients with protein-energy malnutrition, leading to prognostic aggravation in HD patients. In general, serum albumin concentration contributes to the formation of colloid osmotic pressure in vessels and associates with body-fluid movement, mainly between the vessels and the interstitium. In addition, serum albumin concentration was recently shown to positively correlate with the regional cerebral blood flow in patients with liver cirrhosis. \[[@pone.0117474.ref020]\] Based on our results, we propose that an increase in serum albumin concentration might lead to increased rCBF and improved cerebral oxygenation, which can then be measured as cerebral rSO~2~. Therefore, serum albumin concentration would appear to associate not only with nutritional status and prognosis, but also with cerebral oxygenation in HD patients, although its precise mechanism remains uncertain.

Furthermore, in this study, the cerebral rSO~2~ was negatively affected by HD duration, and the annual rSO~2~ decline in HD patients was predicted to be -0.49%/year by simple linear regression analysis ([Fig. 3](#pone.0117474.g003){ref-type="fig"}). It was previously reported that, in HD patients, rCBF to the frontal cortex decreased with an increase in HD duration, resulting in white matter lesions. \[[@pone.0117474.ref021]\] As the cerebral rSO~2~ mainly indicates the condition of rCBF, the negative impact of HD duration on cerebral rSO~2~ might be due to a decrease in the rCBF.

![Correlation between hemodialysis duration and rSO~2~.](pone.0117474.g003){#pone.0117474.g003}

On the other hand, although CaO~2~ and Hb levels significantly correlated with cerebral rSO~2~ in a simple linear regression analysis, these associations disappeared upon multivariate linear regression analysis. Hemoglobin is an important factor in oxygen supply to the peripheral tissues and organs, including the brain; CaO~2~ is a marker for oxygen supply. Thus, cerebral rSO~2~ might be expected to show a strong correlation with Hb and CaO~2~ levels; however, no significant correlations were observed in the present study. Positron emission tomography analysis has revealed an association between the rCBF and Hb levels in HD patients. \[[@pone.0117474.ref022]\] In this report, regional cerebral blood flow decreased significantly, and oxygen metabolism was disrupted despite the increase in Hb levels. Decreased blood cell deformability and increased plasma viscosity resulted in decreased erythrocyte velocity in the cerebral capillaries, leading to an increase in Hb levels. Furthermore, in HD patients, CaO~2~ was reported to be the most important determinant of inter-individual middle cerebral artery (MCA) blood flow velocity variance and variation; in addition, an increase in CaO~2~ could induce the decrease of MCA blood flow velocity via vasoconstrictions in small intracerebral vessels to maintain oxygen delivery to the brain. \[[@pone.0117474.ref023],[@pone.0117474.ref024]\] Indeed, in an experimental study, cerebral O2 transport (CBF × CaO~2~) was regulated at constant levels, independently of alterations in Hb levels and CaO~2~ values. \[[@pone.0117474.ref025]\] Therefore, it is unlikely that oxygen metabolism including rSO~2~ could directly associate with Hb and CaO~2~ levels. Furthermore, ESA administration was reported to reduce the development of brain edema, and preserve the local brain oxygen saturation and brain tissue oxygenation after traumatic brain injury. \[[@pone.0117474.ref026],[@pone.0117474.ref027]\] However, there was no association between cerebral rSO~2~ values and ESA doses in HD patients.

This study included the results obtained from 1 patient with DM, which showed an extremely low cerebral rSO~2~ value. Thus, we analyzed the cerebral rSO~2~ values using the Grubbs-Smirnov rejection test to clarify whether the extremely low rSO~2~ value should be excluded. The test results were not significant; therefore, based on the data obtained in this study, a comparison of cerebral rSO~2~ values was performed for cohorts of HD patients with, and without, DM. The results, which showed significant differences in cerebral rSO~2~ in HD patients with DM compared with those without DM, are interesting, because it was recently suggested that dementia and cognitive impairment were related to DM and chronic kidney disease in patients, including those that underwent HD. \[[@pone.0117474.ref028],[@pone.0117474.ref029]\] In particular, DM has previously been reported to be a significant risk factor for Alzheimer's disease and vascular dementia. \[[@pone.0117474.ref030]\] In addition, an increase in fasting plasma glucose was associated with functional impairment of regional cerebral perfusion; moreover, an improvement in glycemic control led to a reduction in cerebral perfusion deficits. \[[@pone.0117474.ref031]\] In this report, impaired regional cerebral perfusion could be induced by hyperglycemia-induced endothelial dysfunction. Furthermore, dynamic cerebral autoregulation was reported to be impaired even during an early phase in type 2 DM patients. \[[@pone.0117474.ref032]\] In this study, plasma glucose and HbA1c levels were significantly higher in patients with DM than in those without DM; therefore, the significant decrease in cerebral rSO~2~ with DM might be induced by the dysregulation of regional cerebral perfusion due to hyperglycemia-induced endothelial dysfunction. In the present study, there was a difference of \~5% in the cerebral rSO~2~ between HD patients with and without DM, and this value corresponds to cerebral rSO~2~ decline for nearly 10 years, at an annual rate of decline of -0.49%/year for rSO~2~ in HD patients; calculations for the rate of decline were based on the negative correlation between cerebral rSO~2~ and HD duration. Therefore, these results might explain the mechanisms underlying the frequent occurrence of cerebral complications such as dementia and cognitive impairment in HD patients with DM.

This study faced the limitation of a relatively small sample size; therefore, further study is required to fully elucidate the correlation of cerebral rSO~2~ with various clinical parameters.

In conclusion, cerebral rSO~2~ was affected by multiple factors in HD patients, including pH, HD duration, and serum albumin concentration. Furthermore, rSO~2~ was significantly lower in HD patients with DM than in those without DM.
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